Character and meaning of quasi-morphine withdrawal phenomena elicited by methylxanthines.
A quasi-morphine withdrawal syndrome (QMWS) is a pattern of behavior closely resembling the true withdrawal syndrome in the opiate-dependent animal, which can be elicited acutely by a nonopiate drug in an opiate-naive animal. The main criteria proposed for the QMWS, in addition to its resembling the true withdrawal syndrome, are that the effects of opiates and of opiate antagonists on the QMWS should parallel those on true opiate withdrawal. Drugs that wholly or largely fulfill these criteria are 3-isobutyl-1-methylxanthine (IBMX), theophylline, caffeine, ICI 63197, and RO 201724. From the evidence given, it is concluded that these drugs act by inhibiting brain cyclic AMP phosphodiesterase, thus raising the level of cyclic AMP in appropriate neurons. These findings are consistent with the view that the molecular mechanisms of opiate dependence is the hypertrophy of a neuronal cyclic AMP system in compensation for the inhibition by opiate of an adenylate cyclase. Our studies and those of others suggest that: a) very rapid tests for opiate activity and for addictive liability can be devised by use of IBMX; b) opiates may be used clinically to counter poisoning by caffeine or theophylline; and c) a relationship may exist between caffeine consumption and opiate addiction.
D015056:1-Methyl-3-isobutylxanthine / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D012368:4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone / Q000494:pharmacology; D000818:Animals; D002110:Caffeine / Q000494:pharmacology*; D006801:Humans; D007042:Hypoxanthines / Q000494:pharmacology; D009021:Morphine Dependence; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D009294:Narcotics / Q000494:pharmacology; D009293:Opioid-Related Disorders; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D051381:Rats; D013375:Substance Withdrawal Syndrome / Q000209:etiology*; D013805:Theobromine / Q000031:analogs & derivatives / Q000494:pharmacology; D013806:Theophylline / Q000031:analogs & derivatives* / Q000494:pharmacology; D014230:Triazoles / Q000494:pharmacology; D014970:Xanthines / Q000494:pharmacology
D007042:Hypoxanthines; D009292:Narcotic Antagonists; D009294:Narcotics; D010726:Phosphodiesterase Inhibitors; D011743:Pyrimidines; D014230:Triazoles; D014970:Xanthines; C006313:ICI 63197; D012368:4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; D009270:Naloxone; D002110:Caffeine; D013806:Theophylline; C007942:pentifylline; D013805:Theobromine; D015056:1-Methyl-3-isobutylxanthine